US FDA grants approval to Incyte’s Opzelura cream for vitiligo treatment
Pharmaceutical Technology
JULY 19, 2022
as a topical treatment of nonsegmental vitiligo in adults and paediatric patients aged 12 years and above. Opzelura is a topical formulation of a Janus kinase (JAK) inhibitor. With the latest development, Opzelura has became the first treatment for repigmentation in patients with vitiligo to receive FDA approval.
Let's personalize your content